



ASX Announcement
Invitrocue Limited (ASX:IVQ)

Invitrocue Commences Clinical Collaboration with National University Hospital Singapore

08 August 2019: **Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider**, is pleased to announce the commencement of a clinical validation collaboration with National University Hospital (NUH), a leading public teaching hospital in Singapore.

The aim of the clinical study is to validate Invitrocue's Onco-PDO™ drug screening assay, which tests chemotherapy drugs on patient-derived organoids grown from the patient's own tumour cells for patients with refractory solid tumours. The goal is to personalise cancer treatment by selecting chemotherapy drugs that will have the highest response rate for the individual patient.

The validation study with NUH will include patients with breast, ovarian, colorectal and head and neck cancers.

Invitrocue hopes to offer the Onco-PDO™ test at NUH upon completion of the validation study. Each year, the hospital attends to over one million patients.

Cancer is the leading cause of death in Singapore, accounting for 30% of all annual deaths. The majority of cancer patients are diagnosed with late stage disease with no likelihood of cure. Although numerous drugs have been approved for cancer treatment, the response rate of any single chemotherapy drug is 20-30% in the first-line setting, and <5-10% in the refractory setting.

A less than effective drug choice is not only futile but increases the risk of unnecessary side effects which the patient has to endure. It also opens the possibility of further tumour mutations. Unfortunately, no predictive biomarkers currently exist to reliably aid the selection of chemotherapy drugs.

Invitrocue has developed Onco-PDO™ which is capable of generating patient-derived tumour organoids for high-throughput drug screening, that may be used to guide real-time clinical decisions, potentially minimising unnecessary side effects, reducing time and costs spent on multiple chemotherapy regimens, and improving patient outcomes.

The study is now open for enrolment.

Commenting on the clinical study, Dr. Steven Fang, Executive Chairman of Invitrocue, said:

"We are excited to be rolling out this clinical study in Singapore. We see it as a key step in strengthening our Onco-PDO offering that will help more patients get access to personalized cancer treatment worldwide."

For personal use only



For further information, please contact:

Invitrocue

Martin D. Bach

VP Operations

M: +65 6460 0497

E: martind.bach@invitrocue.com

Media & Investor Enquiries

Julia Maguire

The Capital Network

M: +61 419 815 386

E: julia@thecapitalnetwork.com.au

www.invitrocue.com

About Invitrocue (ASX:IVQ)

Invitrocue is a leading healthcare bio-analytic solutions provider including in vitro cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. Invitrocue's Onco-PDO™ technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).

Invitrocue's technology originated in Singapore's Agency for Science, Technology and Research (A*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.

Invitrocue is listed on the Australian Securities Exchange under the ticker IVQ.

To learn more, please visit: www.invitrocue.com

About NUH

The National University Hospital is a tertiary hospital and major referral centre with over 50 medical, surgical and dental specialties, offering a comprehensive suite of specialist care for adults, women and children. It is the only public hospital in Singapore to offer a paediatric kidney and liver transplant programme, in addition to kidney, liver and pancreas transplantation for adults. The Hospital was opened on 24 June 1985 as Singapore's first restructured hospital. Each year, the Hospital attends to more than one million patients.

For personal use only